Investigating the accumulation of aggregated alpha-synuclein protein, which is the defining feature of Parkinson disease.

Investigating loss of connections in populations of neurons that produce dopamine, serotoinin, norepinephrine, and acetylcholine.

Developing an alpha-synuclein imaging agent, which would improve the diagnosis of Parkinson disease and could be used to monitor the effectiveness of disease-modifying treatments.            

Developing treatments that slow or stop the accumulation of alpha-synuclein fibrils in the brain, which could slow or stop the progression of PD.